(2S,4S)-4-羟基-1-苯基甲氧基羰基吡咯烷-2-羧酸叔丁酯 | 224321-05-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S,4S)-4-羟基-1-苯基甲氧基羰基吡咯烷-2-羧酸叔丁酯
• 英文名称: (2S,4S)-4-hydroxy-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid tert-butyl ester
• 英文别名: N-benzyloxycarbonyl-4-L-allo-hydroxyproline tert-butyl ester；N-benzyloxycarbonyl-4-allo-hydroxy-L-proline tert-butyl ester；4-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-tert-butyl ester；1-O-benzyl 2-O-tert-butyl (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylate
• CAS: 224321-05-5
• 化学式: C₁₇H₂₃NO₅
• 分子量: 321.373
• InChiKey: NTIYXHSAWPRZFY-KBPBESRZSA-N

物化性质

• 沸点：
  446.3±45.0 °C(Predicted)
• 密度：
  1.225±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2S,4S)-4-羟基-1-苯基甲氧基羰基吡咯烷-2-羧酸叔丁酯 在 sodium tetrahydroborate 、 magnesium 、 氰基亚甲基三正丁基膦 、 三氟乙酸 、 cobalt(II) chloride 、 mercury dichloride 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 46.0h， 生成 (2S,4R)-4-[2-(diaminomethylideneamino)ethyl]-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid
  参考文献：
  名称：

  限制使用精氨酸-脯氨酸融合氨基酸的肽转变构象和鸟嘌呤基团的构象分析：结合受体后应用于小型心房利钠肽。

  摘要：

  化合物（2S，4S）-和（2S，4R）-4-（2'-胍基乙基）脯氨酸已合成为构象受限的精氨酸。它们的主链轮流适合i +1位置，与精氨酸相比，侧链受到限制。这些类似物被纳入到微型心房利钠多肽中，该多肽在Gly（6）-Arg（7）（）-Met（8）-Asp（9）处具有重要的轮状构象。结构分析表明，Arg（7）与受体结合时构象空间的大小约为整个构象空间的三分之一。

  DOI：

  10.1021/jm030232j
• 作为产物：
  描述：

  1-benzyl-2-(tert-butyl) (S)-4-oxopyrrolidine-1,2-dicarboxylate 在 lithium tri-t-butoxyaluminum hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以98%的产率得到(2S,4S)-4-羟基-1-苯基甲氧基羰基吡咯烷-2-羧酸叔丁酯
  参考文献：
  名称：

  限制使用精氨酸-脯氨酸融合氨基酸的肽转变构象和鸟嘌呤基团的构象分析：结合受体后应用于小型心房利钠肽。

  摘要：

  化合物（2S，4S）-和（2S，4R）-4-（2'-胍基乙基）脯氨酸已合成为构象受限的精氨酸。它们的主链轮流适合i +1位置，与精氨酸相比，侧链受到限制。这些类似物被纳入到微型心房利钠多肽中，该多肽在Gly（6）-Arg（7）（）-Met（8）-Asp（9）处具有重要的轮状构象。结构分析表明，Arg（7）与受体结合时构象空间的大小约为整个构象空间的三分之一。

  DOI：

  10.1021/jm030232j

文献信息

• Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
  申请人：Cottrell M. Kevin

  公开号：US20070161789A1

  公开（公告）日：2007-07-12

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

  本发明涉及式I的化合物：或其药学上可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶NS3-NS4A的活性。因此，它们通过干扰丙型肝炎病毒的生命周期而起作用，并且也可用作抗病毒剂。本发明还涉及包含这些化合物的组合物，无论是用于外体使用还是用于治疗患有HCV感染的患者的给药，以及制备这些化合物的过程。本发明还涉及通过给予本发明的化合物组成物来治疗患者的HCV感染的方法。本发明还涉及制备这些化合物的过程。
• INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE
  申请人：Cottrell Kevin M.

  公开号：US20080125376A1

  公开（公告）日：2008-05-29

  The present invention relates to compounds of formula I: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

  本发明涉及公式I的化合物：或其药学上可接受的盐，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。因此，它们通过干扰乙型肝炎病毒的生命周期来发挥作用，并且可用作抗病毒剂。本发明还涉及药学上可接受的组合物，包括上述化合物，用于体外使用或用于治疗患有HCV感染的患者的给药。本发明还涉及制备该化合物的方法。本发明还涉及通过给予本发明化合物的药物组合物治疗患有HCV感染的患者的方法。
• [EN] 2-AMIDO-4-ARYLOXY-1-CARBONYLPYRROLIDINE DERIVATIVES AS INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE<br/>[FR] INHIBITEURS DES SERINES PROTEASES, EN PARTICULIER DE LA PROTEASE NS3-NS4A DU VIRUS DE L'HEPATITE C (VHC)
  申请人：VERTEX PHARMA

  公开号：WO2005035525A3

  公开（公告）日：2005-10-20
• Synthesis of Conformationally Constrained DTPA Analogs. Incorporation of the Ethylenediamine Units as Aminopyrrolidines
  作者：Matthew A. Williams、Henry Rapoport

  DOI：10.1021/jo00092a022

  日期：1994.7

  The synthesis of conformationally constrained diethylenetriaminepentaacetic acid (DTPA) analogues is an effort to probe the relationship between ligand structure and metal complex stability. In the pursuit of this objective, diastereomerically and enantiomerically pure mono- and bis-pyrrolidine analogues of DTPA have been prepared from trans-4-hydroxy-L-proline. The mono-pyrrolidine chelator 1 was constructed from a single hydroxyproline unit and an ethylenediamine moiety while two hydroxyproline-derived fragments 4e or 14b and 9b were coupled by N-alkylation of a triflate to afford the core bis-pyrrolidine structures: optically active 10 and meso-15. Deprotection of the triamine pentaesters 12 and 17 afforded the triamine pentaacetic acids 2 and 3 as their hydrochloride salts. The stereochemical homogeneity of precursor esters 12 and 17 was determined by HPLC using authentic epimeric standards to establish that essentially no racemization of the original amino acid a-center had occurred. Some loss of stereochemical homogeniety was encountered in the synthesis of 10 and 15 by N-alkylation of aminoproline 9b with a hydroxyproline-derived triflate, which had proceeded with some retention of configuration. The diastereomeric impurities were removed by crystallization of the respective benzyl carbamates. Bis-pyrrolidine pentaacids 2 and 3 formed isolable chelates with gadolinium and lutetium. A comparision of the lutetium chelates of 2 and 3 by NMR revealed significant differences which were reflective of a rigid structure with 2, while metal complexation with 3 was structurally less defined.
• Yelin; Onoprienko, Russian Journal of Bioorganic Chemistry, 1998, vol. 24, # 9, p. 594 - 598
  作者：Yelin、Onoprienko

  DOI：——

  日期：——